Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 11/20 | 0.43 |
| ▸ | FLT1 | P17948 | 3/20 | 0.42 |
| ▸ | FLT4 | P35916 | 3/20 | 0.42 |
| ▸ | BMP4 | P12644 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10182972 | 0.84 | PIK3CG (0.37) | KDRBMP4PIK3CG | |
| SCHEMBL10182958 | 0.84 | KIF11 (0.50) | KIF11KDRPIK3CAPIK3CG | |
| SCHEMBL10183057 | 0.80 | BMP4 (0.37) | KDRBMP4 | |
| SCHEMBL10182971 | 0.80 | JAK1 (0.40) | KDRBMP4MAP4K4MAPT | |
| SCHEMBL10183085 | 0.79 | ALOX5AP (0.40) | LMNAMAPT | |
| SCHEMBL26766295 | 0.79 | KDR (0.49) | KIF11KDRFLT1FLT4BMP4 | |
| SCHEMBL10182940 | 0.79 | JAK1 (0.38) | PIK3CAPIK3CG | |
| SCHEMBL10182966 | 0.78 | ACVR2A (0.47) | BMP4 | |
| SCHEMBL10183063 | 0.78 | KIT (0.32) | DYRK1AMAPT | |
| SCHEMBL10182956 | 0.78 | JAK1 (0.38) | KDRBMP4DYRK1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KIF11 3648/4885KDR 929/4885FLT1 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.